The first of its kind to enter the clinic, sabirnetug, an immunotherapy drug candidate, is designed to selectively target toxic soluble amyloid beta oligomers (AβOs). As AβOs are an early trigger and persistent driver of Alzheimer’s-associated pathology and neurodegeneration, sabirnetug addresses an underlying cause of Alzheimer’s disease by preventing toxic AβOs from binding to dendritic spines and helping preserve neuronal function.